Viking Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viking Therapeutics (VKTX).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

1S.Buy

15Buy

2Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$95Upside to Avg. PT+243.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	UBS	Joon Lee	Initiate	Buy	$94
Oct 7, 2026	Truist Securities	Joon Lee	PT Cut	Buy	$87→$85
Sep 23, 2026	Truist Securities	Joon Lee	PT Raise	Buy	$83→$87
Aug 11, 2026	JP Morgan	Hardik Parikh	PT Cut	Overweight	$75→$65
Jul 30, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$107→$114
May 28, 2026	Lake Street	Daniel Brims	Initiate	Buy	$89
May 1, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$125
Apr 30, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Cut	Overweight	$105→$100
Mar 23, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
Nov 12, 2025	Canaccord Genuity	Edward Nash	PT Raise	Buy	$106→$107
Oct 29, 2025	Canaccord Genuity	Edward Nash	Initiate	Buy	$106
Oct 24, 2025	JP Morgan	Hardik Parikh	PT Cut	Overweight	$80→$75
Oct 23, 2025	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$98→$102
Sep 29, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
Sep 22, 2025	BTIG	Justin Zelin	Maintained	Buy	$125
Aug 19, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
Jul 24, 2025	Raymond James	Ryan Deschner	PT Cut	Strong Buy	$125→$122
Jul 24, 2025	Citigroup	David Lebowitz	PT Raise	Neutral	$31→$38
Jun 25, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
Apr 28, 2025	Cantor Fitzgerald	Steven Seedhouse	Initiate	Overweight	$104

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

UBS analyst Joon Lee initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $94.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $87 to $85.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $83 to $87.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $75 to $65.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $107 to $114.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89

Lake Street analyst Daniel Brims initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $89.

Benzinga Newsdesk

Viking Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Viking Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

PRO
Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89

People Also Watch

People Also Watch

Viking Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Viking Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PROTruist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PROTruist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PROJP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

PROCanaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

PROLake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89

People Also Watch

People Also Watch

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

PRO
Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89